index - CRCL- Plateforme Ex-Vivo

François Virard, Stéphane Giraud, Mélanie Bonnet, Léa Magadoux, Laetitia Martin, et al.. Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death. Nature Communications, 2024, 15, pp.7037. ⟨10.1038/s41467-024-51275-z⟩. ⟨hal-04676566⟩
É. Mathian, Y. Drouet, A. Sexton-Oates, M.G. Papotti, G. Pelosi, et al.. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. ESMO Open, 2024, 9 (6), pp.103591. ⟨10.1016/j.esmoop.2024.103591⟩. ⟨hal-04655442⟩
Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, et al.. Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. Cancer Medicine, 2024, 13 (7), pp.e7115. ⟨10.1002/cam4.7115⟩. ⟨hal-04646005⟩
Clara Savary, Léa Luciana, Paul Huchedé, Arthur Tourbez, Claire Coquet, et al.. Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers. Cell Reports Medicine, 2023, 4, ⟨10.1016/j.xcrm.2023.101339⟩. ⟨hal-04374201⟩
Benjamin Ducarouge, Anna-Rita Redavid, Camille Victoor, Ruxanda Chira, Aurélien Fonseca, et al.. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor. Cell Death and Differentiation, 2023, 30 (10), pp.2201-2212. ⟨10.1038/s41418-023-01209-x⟩. ⟨hal-04253805⟩
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, et al.. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. Cancers, 2023, 15, ⟨10.3390/cancers15133441⟩. ⟨hal-04209734⟩

Derniers manuscrits de la plateforme

Chiffres clés